ALSO NOTED: Bio-Rad buying DiaMed; Medarex names new CEO;and much more...

> Bio-Rad Laboratories has agreed to pay $390 million for DiaMed, which makes and sells reagents and technology for blood typing and screening. The deal gives Bio-Rad a company with $200 million in annual sales and 800 employees. Report

> Medarex has named Howard H. Pien president and CEO. Report

> Millennium Pharmaceuticals has initiated patient dosing in a clinical program designed to evaluate MLN0002, a monoclonal antibody that binds to the T-cell integrin alpha 4 beta 7 with potential in a variety of gastrointestinal diseases, including ulcerative colitis. Release

> The FDA has given DUSA Pharmaceuticals orphan status for Levulan Photodynamic Therapy as a treatment of esophageal dysplasia. Report

And Finally... CollaGenex Pharmaceuticals is paying $1.5 million up front to QuatRx for the right to develop and commercialize becocalcidiol, a mid-stage psoriasis treatment. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.